AstraZeneca's Breztri Receives FDA Approval for Asthma Treatment

The U.S. Food and Drug Administration has granted approval for AstraZeneca's Breztri, a triple combination therapy. This medication is now cleared for the ongoing treatment of asthma in individuals aged 12 and older. Breztri had previously received approval for use in managing chronic obstructive pulmonary disease.